| p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer J Liu, D He, L Cheng, C Huang, Y Zhang, X Rao, Y Kong, C Li, Z Zhang, ... Oncogene 39 (19), 3939-3951, 2020 | 83 | 2020 |
| NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells E Farah, C Li, L Cheng, Y Kong, NA Lanman, P Pascuzzi, GR Lorenz, ... Journal of Biological Chemistry 294 (21), 8543-8554, 2019 | 55 | 2019 |
| Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration‐resistant prostate cancer X Chen, J Liu, L Cheng, C Li, Z Zhang, Y Bai, R Wang, T Han, C Huang, ... The Prostate 80 (3), 256-266, 2020 | 27 | 2020 |
| Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance C Li, NA Lanman, Y Kong, D He, F Mao, E Farah, Y Zhang, J Liu, C Wang, ... Journal of Biological Chemistry 295 (16), 5470-5483, 2020 | 10 | 2020 |
| The kinase PLK1 promotes the development of Kras/Tp53-mutant lung adenocarcinoma through transcriptional activation of the receptor RET Y Kong, DB Allison, Q Zhang, D He, Y Li, F Mao, C Li, Z Li, Y Zhang, ... Science signaling 15 (754), eabj4009, 2022 | 9 | 2022 |
| Epigenetics in prostate cancer treatment K Jones, Y Zhang, Y Kong, E Farah, R Wang, C Li, X Wang, ZZ Zhang, ... Journal of translational genetics and genomics 5, 341, 2021 | 9 | 2021 |
| A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer J Liu, Y Zhao, D He, KM Jones, S Tang, DB Allison, Y Zhang, J Chen, ... Cell Reports Medicine 4 (4), 2023 | 4 | 2023 |
| Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer F Mao, Y Kong, J Liu, X Rao, C Li, K Donahue, Y Zhang, K Jones, ... The Prostate 82 (8), 917-932, 2022 | 4 | 2022 |
| GSTM2 is a key molecular determinant of resistance to SG-ARIs C Li, J Liu, D He, F Mao, X Rao, Y Zhao, NA Lanman, M Kazemian, ... Oncogene 41 (40), 4498-4511, 2022 | 1 | 2022 |
| Phosphorylation of AHR by PLK1 promotes metastasis of LUAD via DIO2-TH signaling C Li, DB Allison, D He, F Mao, X Wang, P Rychahou, IA Imam, Y Kong, ... PLoS Genetics 19 (11), e1011017, 2023 | | 2023 |
| Single-cell analysis characterizes PLK1 as a catalyst of an immunosuppressive tumor microenvironment in LUAD XL Yifan Kong, Chaohao Li, Jinpeng Liu, Min Zhang, Derek B Allison, Faisal ... bioRxiv, 2023.08. 02.551692, 2023 | | 2023 |
| Plk1 phosphorylation of PHGDH to regulate serine metabolism X Rao, DB Allison, RM Flight, Y Wu, T Scott, D He, RX Wang, Z Li, C Li, ... Cancer Research 83 (7_Supplement), 3673-3673, 2023 | | 2023 |
| Phosphorylation of AHR by PLK1 promotes metastasis of LUAD via upregulation of DIO2 C Li, D He, F Mao, X Wang, Y Hao, Y Kong, CF Brainson, J Liu, Y Zhang, ... Cancer Research 83 (7_Supplement), 2578-2578, 2023 | | 2023 |
| Taxol-elevated PLK1 overcomes BETi-resistant in prostate cancer via triggering phosphorylation-dependent degradation of BRD4 Y Zhang, KW Fong, F Mao, R Wang, Y Kong, C Li, J Liu, Z Li, DB Allison, ... Cancer Research 83 (7_Supplement), 4992-4992, 2023 | | 2023 |
| PLK1 promotes the metastasis and drug resistance in melanoma F Mao, Y Kong, C Li, Y Zhang, X Rao, Q Zhang, X Wang, Z Li, X Liu Cancer Research 83 (7_Supplement), 4997-4997, 2023 | | 2023 |
| A kinome-wide CRISPR screen identifies CK1α as a novel target to overcome enzalutamide resistance of prostate cancer J Liu, Y Zhao, D He, K Jones, S Tang, D Allison, Y Zhang, J Chen, ... | | 2022 |
| NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells Elia Farah1, Chaohao Li2, Lijun Cheng3, Yifan Kong2, Nadia A … E Farah, C Li, L Cheng, Y Kong, NA Lanman, P Pascuzzi | | |
| OVERCOMING RESISTANCE TO SG-ARIS IN CASTRATION-RESISTANT PROSTATE CANCER C Li | | |
